No Data
No Data
Incyte Faces Pipeline Setbacks: Hold Rating Amid Uncertainties
Trending Stocks Today | Symbotic Soars 23.06% Post-Market
Express News | Incyte Shares Extend After the Bell Losses, Last Down 12% at $67.65 Following Drug Study Update
Express News | Incyte - Data From Phase 2 Study Evaluating Mrgprx4 (Incb000547) in Cholestatic Pruritus (Cp) Does Not Support Further Development
Express News | Incyte - It Will Pause Enrollment in Ongoing Phase 2 Study of Mrgprx2 (Incb000262) in Chronic Spontaneous Urticaria
Express News | Incyte Provides Update on Early Phase Mrgprx2 and Mrgprx4 Programs
No Data
No Data